| 摘要 |
FIELD: medicine, pediatric gastroenterology. ^ SUBSTANCE: the present innovation deals with selecting children with functional dyspepsia at helicobacteriosis for the purpose to carry out anti-helicobacter therapy. So, one should detect the following signs in a child: hypertrophic gastropathy in gastric antral department, relapses of dyspepsia symptoms during 1 yr and more, despite treatment by applying antacids and anti-secretory preparations, inheritance on ulcerous disease, previously observed erosions in gastroduodenal area; and in case of any of the above-mentioned signs in a child it is necessary to fulfill anti-helicobacter therapy, and in case of the absence of the above-mentioned signs this therapy should not be carried out. This innovation provides differentiated approach to therapy, it, also, enables to avoid groundless medicinal loading upon a child and decrease financial expenses for the treatment. ^ EFFECT: higher efficiency of individualization. ^ 4 ex |
